Trulieve Cannabis Corp. TRLV
- Market cap
- $2.4B
- P/E
- —
Follow TRLV
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 6.68 | 7.46 | 5.74 | 23.10 | 6.39 | 3.42 | 4.44 | 3.02 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | 21.00 | 16.23 | 33.45 | 53.73 | 27.44 | 7.84 | 14.50 | 11.83 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | 5,000 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Trulieve Cannabis Corp. (TRLV) Latest News
22 Sep
Trulieve Cannabis Corp. announced it has been added to the S&P Total Market Index, the S&P Completion Index, and the S&P Health Care sub-indices. CEO Kim Rivers says inclusion increases visibility, improves liquidity, and attracts new institutional investors after its NYSE listing and domestication to the U.S. Trulieve, a vertically integrated MSO with operations in Florida, Georgia, Pennsylvania, and West Virginia, positions itself for accelerated growth through its hub strategy and branded products. Inclusion in major indices typically enhances liquidity and institutional demand, positively impacting share performance.
18 Aug
Trulieve Cannabis Corp. will ring the closing bell at the New York Stock Exchange as the first U.S. cannabis company listed on the NYSE. NYSE listing boosts visibility and market legitimacy for the company without changing operations or financial results.
9 Aug
Trulieve Cannabis Q2 earnings call highlights financial results, operational updates and strategic outlook for the cannabis company. Q2 earnings data offers routine insight into financial performance without signaling major strategic shifts.
7 Aug
Trulieve Cannabis reports steeper losses and lower sales. Questions arise whether the current valuation discount is justified given the weaker results. Steeper losses and lower sales pressure near-term stock performance and investor sentiment without fundamentally altering long-term trajectory.
Trulieve Cannabis Corp. released its second quarter 2026 financial results. Quarterly results provide updated financial metrics that may shift near-term investor views without altering core operations.
Trulieve Cannabis Corp. released second quarter 2026 financial results. Quarterly results update financial performance and may shift near-term investor sentiment.
5 Aug
GTBIF stock faces buy, hold or sell analysis after Q2 earnings release. Post-earnings stock advice can sway short-term investor decisions but rarely shifts company fundamentals.
1 Jul
Trulieve Cannabis Corp. marked the launch of medical cannabis in Georgia by completing its first sale in the state. Georgia market entry adds revenue stream but scale remains limited by single-state scope and regulatory constraints.
22 Jun
Trulieve Cannabis Corp. completes historic NYSE listing, prompting assessment of whether the stock remains a buy amid evolving market conditions. NYSE listing marks major strategic move capable of significantly altering market access and company trajectory.
14 Jun
Trulieve Cannabis Corp. (TRLV) becomes the first U.S. marijuana stock to trade on the NYSE, expanding access for investors and signaling greater mainstream acceptance of cannabis equities. NYSE listing boosts Trulieve's visibility, liquidity, and legitimacy, materially shifting its market trajectory and investor base.
11 Jun
Trulieve Cannabis Corp. (NYSE:TRLV) is approaching break-even status in its financial performance. Nearing break-even indicates significant improvement in financial trajectory for Trulieve Cannabis Corp.